TY - JOUR
T1 - Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients
AU - Tu, Min Yu
AU - Chen, Hsiao Ling
AU - Tung, Yu Tang
AU - Kao, Chao Chih
AU - Hu, Fu Chang
AU - Chen, Chuan Mu
N1 - Funding Information:
This research was supported in part by grants NSC-99-2324-B-005-017-CC1, NSC-101- 2324-B-005-002-CC1, MOST-101-2313-B-005-014- MY3, and MOST-104-2313-B-005-043-MY3 from the National Science Council and the Ministry of Education, Taiwan, Republic of China, under the Aiming for the Top University plan (ATU-103-S0508). The funders had no role in this design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to thank Dr. Fu-Chang Hu, National Center of Excellence for General Clinical Trial and Research, National Taiwan University Hospital and College of Public Health, National Taiwan University, for his guidance in regression analysis in statistical computing.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Milk products are good sources of calcium that may reduce bone resorption and help prevent bone loss as well as promote bone remodeling and increase bone formation. Kefir is a product made by kefir grains that degrade milk proteins into various peptides with healthpromoting effects, including antithrombotic, antimicrobial and calcium-absorption enhancing bioactivities. In a controlled, parallel, double-blind intervention study over 6 months, we investigated the effects of kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg) and bone metabolism in 40 osteoporosis patients, and compared them with CaCO3 alone without kefir supplements. Bone turnover markers were measured in fasting blood samples collected before therapy and at 1, 3, and 6 months. Bone mineral density (BMD) values at the spine, total hip, and hip femoral neck were assessed by dual-energy x-ray absorptiometry (DXA) at baseline and at 6 months. Among patients treated with kefir-fermented milk, the relationships between baseline turnover and 6 months changes in DXA-determined BMD were significantly improved. The serum β Cterminal telopeptide of type I collagen (β-CTX) in those with T-scores > -1 patients significantly decreased after three months treatment. The formation marker serum osteocalcin (OC) turned from negative to positive after 6 months, representing the effect of kefir treatment. Serum parathyroid hormone (PTH) increased significantly after treatment with kefir, but decreased significantly in the control group. PTH may promote bone remodeling after treatment with kefir for 6 months. In this pilot study, we concluded that kefir-fermented milk therapy was associated with short-term changes in turnover and greater 6-month increases in hip BMD among osteoporotic patients.
AB - Milk products are good sources of calcium that may reduce bone resorption and help prevent bone loss as well as promote bone remodeling and increase bone formation. Kefir is a product made by kefir grains that degrade milk proteins into various peptides with healthpromoting effects, including antithrombotic, antimicrobial and calcium-absorption enhancing bioactivities. In a controlled, parallel, double-blind intervention study over 6 months, we investigated the effects of kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg) and bone metabolism in 40 osteoporosis patients, and compared them with CaCO3 alone without kefir supplements. Bone turnover markers were measured in fasting blood samples collected before therapy and at 1, 3, and 6 months. Bone mineral density (BMD) values at the spine, total hip, and hip femoral neck were assessed by dual-energy x-ray absorptiometry (DXA) at baseline and at 6 months. Among patients treated with kefir-fermented milk, the relationships between baseline turnover and 6 months changes in DXA-determined BMD were significantly improved. The serum β Cterminal telopeptide of type I collagen (β-CTX) in those with T-scores > -1 patients significantly decreased after three months treatment. The formation marker serum osteocalcin (OC) turned from negative to positive after 6 months, representing the effect of kefir treatment. Serum parathyroid hormone (PTH) increased significantly after treatment with kefir, but decreased significantly in the control group. PTH may promote bone remodeling after treatment with kefir for 6 months. In this pilot study, we concluded that kefir-fermented milk therapy was associated with short-term changes in turnover and greater 6-month increases in hip BMD among osteoporotic patients.
UR - http://www.scopus.com/inward/record.url?scp=84955620092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955620092&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0144231
DO - 10.1371/journal.pone.0144231
M3 - Article
C2 - 26655888
AN - SCOPUS:84955620092
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 12
M1 - e0144231
ER -